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Temporal lobe epilepsy (TLE) is a chronic neurodegenerative disease with a high prevalence
of psychiatric disorders. Temporal neocortex contributes to either seizure propagation or
generation in TLE, a situation that has been associated with alterations of the γ-amino-
butyric acid (GABA) system. On the other hand, an impaired neurotransmission mediated
by GABA in temporal neocortex has also been involved with the pathophysiology of psychi-
atric disorders. In spite of these situations, the role of the necortical GABA system in the
comorbidity of TLE and mood disorders has not been investigated. The present study was
designed to identify alterations in the GABA system such as binding to GABAA and GABAB
receptors and benzodiazepine site, the tissue content of GABA and the expression of the
mRNA encoding the α1–6, β1–3, and γ GABAA subunits, in the temporal neocortex of sur-
gically treated patients with TLE with and without anxiety, and/or depression. Neocortex
of patients with TLE and comorbid anxiety and/or depression showed increased expres-
sion of the mRNA encoding the γ2-subunit, reduced GABAB-induced G-protein activation
in spite of elevated GABAB binding, and lower tissue content of GABA when compared to
autopsy controls. Some of these changes significantly correlated with seizure frequency
and duration of epilepsy. The results obtained suggest a dysfunction of the GABAergic
neurotransmission in temporal neocortex of patients withTLE and comorbid anxiety and/or
depression that could be also influenced by clinical factors such as seizure frequency and
duration of illness.
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INTRODUCTION
It is known that a high percentage of patients with epilepsy have
comorbid interictal psychiatric disorders (Briellmann et al., 2007;
Kanner, 2011). This situation can be explained by pathophysiolog-
ical mechanisms associated with specific neurotransmitters in the
brain areas involved in both, epilepsy and psychiatric conditions
(Rocha et al., 2014).
Temporal neocortex is a paralimbic structure that belongs to a
visceromotor system associated with mood, emotions, and visceral
reactions to emotional stimuli (Beauregard et al., 1988; Partiot
et al., 1995; Ongür et al., 1998; Drevets et al., 2008). Neuroanatomi-
cal studies in non-human primates indicate that temporal cortex is
involved in the sensory integration as well as codification of affec-
tive characteristics of stimuli (Ongür and Price, 2000; Saleem et al.,
2007). Abnormalities in gray matter volume and glucose metab-
olism have been detected in the temporal neocortex of patients
with mood disorders (Ongür et al., 2003). Temporal neocortex
of patients with depression presents overactivation (Sheline et al.,
2009) as well as abnormalities in cell communication and signal
transduction systems identified by transcriptional profiling (Aston
et al., 2005). Alterations of γ-amino-butyric acid (GABA) system
in temporal neocortex have been proposed to participate in the
pathophysiology of mood disorders (Nikolaus et al., 2010).
On the other hand, abnormal neurotransmission mediated by
GABA system in the cortex has been suggested to play an important
role in seizure generation and/or propagation (Chagnac-Amitai
and Connors, 1989) as well as in the neuronal overactivation
detected in this brain of patients with temporal lobe epilepsy
(TLE) (Avoli et al., 1995; Koepp et al., 2000; Teichgräber et al.,
2009). Nevertheless, studies aimed to identify alterations on GABA
receptor binding in the temporal neocortex of patients with phar-
macoresistant TLE have shown dissimilar results (la Fougère et al.,
2009).
Although previous studies suggest that GABA disturbances
in the temporal neocortex participate in the pathophysiology of
TLE and comorbid mood disorders (Kondziella et al., 2007), this
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idea has not been investigated. The present study was focused
to evaluate a possible association between alterations in the
GABAergic system in the temporal neocortex of patients with
pharmacoresistant TLE and comorbid anxiety and/or depression.
Experiments were designed to analyze the binding to GABAA
receptors involved in tonic ([3H]-Muscimol) and phasic ([3H]-
Flunitrazepam) neurotransmission, as well as GABAB receptor
binding. We also evaluated the G-protein activation mediated by
GABAB receptors, the tissue content of GABA and the mRNA
expression of some GABAA receptor subunits. Values obtained
were correlated with clinical data to identify those clinical factors
that could be involved in specific alterations of the GABAergic
system.
MATERIALS AND METHODS
PATIENTS CRITERIA AND SURGICAL SAMPLES
Biopsy samples of temporal neocortex were obtained from 26
patients with diagnosis of pharmacoresistant TLE: 16 patients
with mesial TLE, nine patients with TLE secondary to tumor or
lesion, and one patient with dual pathology namely mesial TLE
and tumor. All patients underwent epilepsy surgery after been
submitted to an extensive pre-surgical evaluation according to the
protocol of the Epilepsy Surgery Program of the National Insti-
tute of Neurology and Neurosurgery “Manuel Velasco Suarez,” in
Mexico (Table S1 in Supplementary Material).
The pre-surgical evaluation consisted of neurological evalua-
tion, electroencephalogram (EEG) and video-EEG recordings, sin-
gle photon emission computed tomography (SPECT) or positron
emission tomography (PET), neuropsychological and neuropsy-
chiatric evaluation, and magnetic resonance imaging (MRI). MRI
findings were in concordance with those found in EEG recordings.
During the neurological evaluation, prevalence of depression
and anxiety disorders was established using the Structured Clin-
ical Interview for DSM-IV Axis I (SCID-I) (First et al., 1999)
applied by a Psychiatrist, who was blinded to the epilepsy diag-
nosis. Spanish version of the Hospital Anxiety and Depression
Scale (HADS) were applied to all patients to identify symptoms
of anxiety and/or depression. HADS has been previously vali-
dated in a Spanish population (Herrero et al., 2003; Gómez-Arias
et al., 2012). HADS scale considers symptoms over the previous
week and is not affected by coexisting general medical conditions.
Patients with other psychiatric or somatic disturbances interfering
with mood disorders, such as addiction, were excluded from the
present study.
The neurosurgeon (Mario Alonso-Vanegas) carried out all the
surgeries. Patients with mesial TLE underwent epilepsy surgery
using a T2 or T3 transtemporal approach and guided by elec-
trocorticographic (ECoG) signals recorded from the brain surface
(4× 8-electrode grids, Ad-Tech, Racine, WI). The epilepsy surgery
consisted of unilateral amygdalo-hippocampectomy that included
removal of the uncus and parahippocampal gyrus, and the tailored
resection of T2 and T3 (San-Juan et al., 2011). Patients with tumor
or lesion, with and without TLE had a similar surgical procedure
unaided by ECoG recordings, with standard temporal neocorti-
cal resection. In these patients, amygdalo-hippocampectomy was
performed depending on the localization of the lesion or tumor
and neuropsychological findings. After resection, T2 and T3 gyri
were immediately frozen in milled dry ice and kept at −70°C
until processing. When the tumor or lesion was restricted to the
temporal neocortex, samples from the margins of the lesion were
used for present study. The protocol did not include biopsies with
tumor, cortical malformations or any cortical alteration identified
by neuropathological evaluation.
The present study was approved by the scientific commit-
tees of the institutions involved in this research and informed
authorization and consent were obtained from each patient.
AUTORADIOGRAPHY EXPERIMENTS
Previous studies specify that receptor binding and guanosine 5′-
O-[γ-thio [35S]] triphosphate ([35S]GTPγS) binding stimulation
by selective agonists to GABAB receptors are preserved for sev-
eral hours after death (González-Maeso et al., 2000), while longer
post-mortem delay has been associated with increased binding
to benzodiazepine (BDZ) sites (Whitehouse et al., 1984). Con-
sidering this information, binding values acquired from autopsies
of six men who died as consequence of diverse causes without
clinical data of neurologic or psychiatric disorders with a post-
mortem interval of 2–14 h were compared to those obtained from
the patients with pharmacoresistant TLE (Table S1 in Supplemen-
tary Material). T2 and T3 gyri were dissected at the time of the
autopsy and quickly kept at −70°C. For each autoradiography
assay, tissue samples of the different patients and autopsies were
processed together in order to reduce the experimental variability.
Preparation of tissue sections
Frozen sections of 20µm were cut in a cryostat, thaw-mounted on
gelatin-coated slides, and kept again at −70°C. Serial and parallel
sections were obtained from each biopsy/autopsy for subsequent
quantitative and functional autoradiography procedures.
Quantitative autoradiography
Table 1 includes a summary of the different protocols for the
quantitative autoradiography experiments. Brain sections were
removed from the freezer, dried in a stream of cool air, and imme-
diately washed to eliminate endogenous ligands. Then, sections
were incubated in a solution with the specific ligand labeled with
tritium ([3H]), in presence or absence of a non-labeled specific
ligand. The specific binding values were established from the dif-
ference of values obtained from both experimental conditions.
Incubation was concluded with two consecutive washes in buffer
solution and a final rinsed with distilled water was carried out for
2 s at 4°C. Slices were quickly dried in a mild steam of cold air.
Slices from patients and autopsies as well as [3H] standards
(Amersham) were arranged together in X-ray cassettes and all of
them were exposed to [3H]-sensitive film (Kodak MR) at 22°C.
After the appropriate exposure time (see Table 1), the film was
developed at 18–20°C in Kodak D19 developer and fast fixer.
Optical densities of cortical layers of each tissue sample were
evaluated in three different sections using the JAVA Jandel image
analysis software. Temporal neocortex was subdivided for autora-
diographic analysis into an outer layer (cortical layers I and II),
middle layer (cortical layers III and IV), and an inner layer (cor-
tical layers V and VI). The distribution of receptor binding sites,
as revealed by optical densities of the autoradiograms obtained
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Table 1 | Conditions for quantitative autoradiography experiments.
Binding Ligand (nM) and SA Buffer pH 7.4 Incubation Exposition
(RT)
Non-labeled
ligand
GABAA [3H]-Muscimol (20 nM) 20 Ci/mmol Tris Citrate (50 mM) 45 min at 4°C 8 weeks GABA (10µM)
GABAB [3H]-CGP54626 (4 nM) 30 Ci/mmol Tris–HCl (50 mM) and
CaCl2 (10 mM)
90 min at 22°C 12 weeks CGP55845 (100µM)
Benzodiazepines [3H]-Flunitrazepam (2 nM) 85.2 Ci/mmol Tris–HCl (170 mM) 45 min at 4°C 3 weeks Clonazepam (1µM)
SA, specific activity; RT, room temperature.
by outlining each layer, was matched to the cortical layers visu-
alized on the sections counter-stained with 0.5% Cresyl Violet
(Figure 2). Finally, the generation of a standard curve using the
optical density values of the standards, the specific activity of each
[3H]-labeled ligand, and tissue thickness (20µm) was used to
convert radioactivity values in fmol/mg of protein.
Functional autoradiography
Sections were washed in Tris buffer (50 mM Tris–HCl, 3 mM
MgCl2, 0.2 mM EGTA, 100 mM NaCl, pH 7.4 at 25°C for 10 min),
then incubated in the assay buffer containing 2 mM GDP (25°C
for 15 min). GABAB-induced G-protein activation was evaluated
in sections subsequently incubated in the same assay buffer with
2 mM GDP and 0.04 nM [35S]GTPγS (25°C for 2 h) in the pres-
ence of baclofen (100µM), a GABAB receptor agonist. In parallel
sections, the effects of baclofen were evaluated in the presence
of a GABAB antagonist (CGP55845A, 10 mM). Basal binding was
determined in sections incubated in similar conditions, but lack-
ing agonist and antagonist drugs. Thereafter, slices were washed
twice for 2 min each in assay buffer (4°C, pH 7.4) and once in dis-
tilled water (4°C). Sections from autopsies and patients were dried
overnight and exposed to film (Kodak-MR) for 5 days at 22°C in X-
ray cassettes containing [14C] microscales (American Radiolabeled
Chemicals, Inc.). Optical density analysis of the different corti-
cal layers was carried out as previously described for quantitative
autoradiographic experiments. Results obtained from the different
assays were expressed as nanocuries of [35S] per milligram of tis-
sue. Net agonist-stimulated [35S]GTPγS binding was calculated in
percentage by subtracting basal binding from agonist-stimulated
binding.
SEMIQUANTITATIVE RT-PCR ANALYSIS
Expression levels of human GABAA receptor subunit mRNAs (α1-
to α6-, β1- to β3-, and γ1- to γ3-subunits) were determined from
resected human tissues of autopsies and patients with pharma-
coresisant TLE by semiquantitative RT-polymerase chain reaction
(PCR) procedure. For this purpose, a fragment was obtained from
each brain sample of patients with epilepsy and from the autop-
sies. The fragmentation was done maintaining the tissue frozen, a
situation that allowed to preserve the mRNA.
Total RNA was isolated using the TriPure isolation Reagent
(ROCHE, USA) according to the manufacturer’s instructions.
Reverse transcriptase (RT) of 3µg of total RNA was synthe-
sized to single-stranded cDNA using random primers (Promega,
USA) and 200 U of M-MuLV RT (New England Biolabs, USA)
in a total reaction volume of 10µl. The RT reaction was per-
formed for 10 min at 25°C, 50 min at 37°C and 15 min at 70°C
according to the manufacturer’s instructions. After RT, 20µl of
ultrapure-grade water was added to the final reaction. Gene ampli-
fications were performed using 1µl of diluted cDNA, 0.2–0.4µl
of 60 mM MgCl2, 0.2µl of dNTP mix solution (Promega, USA),
0.2µl of each primer pair (10 mM) and 0.2µl of Taq DNA poly-
merase (Invitrogen, USA) in a total volume of 10µl. The final
MgCl2 concentration depended on each gene evaluated. The PCR
was carried out in a DNA Thermal Cycler (Bio-Rad, USA) with
a cycle program of 94°C for 3 min, 30–35 cycles at 94°C for 30 s,
54–58°C for 20–30 s, 72°C for 30–40 s, and one cycle of 72°C for
10 min. The cycle program was performed until the exponential
phase was achieved; other PCR conditions were performed indi-
vidually. The PCR products were separated by electrophoresis in
a 2% agarose gel (Invitrogen) in TAE buffer at 75 V. The gels were
captured and evaluated in an Alpha Innotech corporation IS-1000
digital imaging system, using EtBr (0.6 g/ml by gel) under UV light.
Genomic DNA contamination was checked by carrying samples
through a PCR procedure without adding reverse transcriptase.
The bands from images were analyzed using the NIH Image J
system version 1.46 (http://imagej.nih.gov/ij/) and quantified as
values of integrated density. The relative value of each gene was a
ratio between the expression of each gene and β-actin as control.
TISSUE CONTENT OF GABA
Evidence exists indicating a significant degradation by proteoly-
sis of the GABA-synthesizing enzyme (GAD) and reduced GABA
tissue content in the brain tissue within hours after death (Lowe
et al., 1988; Martin et al., 2003). Since this condition can represent a
potential problem in the evaluation of the tissue content of GABA
in autopsy samples, temporal neocortex of six patients (four men
and two women) submitted to surgery with diagnosis of cerebral
tumor without epilepsy was used as control tissue to be compared
with values obtained from patients with pharmacoresistant TLE
(Table S1 in Supplementary Material).
Gray matter (50–100 mg) of each brain sample was thawed
and manually homogenized in perchloric acid (0.1 M, J. T. Baker).
The homogenates were centrifugated at 13,200 rpm (15 min at
4°C) using a centrifuge (Eppendorf 5415R). Samples of the super-
natant (100µl) previously filtered (Nalgene filters of 0.45µm)
were suspended in 0.1 M perchloric acid in a 1:250 proportion.
Subsequently, 20µl of the filtered supernatant were mixed with
6µl of o-phthalaldehyde (OPA) and agitated for 30 s. Two min-
utes later, the mixture was injected into the solvent stream of a high
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 442 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rocha et al. GABA, epilepsy, and comorbid anxiety and depression
performance liquid chromatography (HPLC) system. For GABA
quantification, the procedure required that OPA-amino acid were
separated on a reversed-phase 3.9× 150 mm column (Nova-Pack,
4µm, C18, Waters®) with solution A (sodium acetate dissolved in
90% miliQ water and 10% methanol; pH 5.75 with glacial acetic
acid) as aqueous solvent and solution B as the other mobile phase
(20% solution A and 80% methanol; pH 6.75 with glacial acetic
acid) at a flow rate of 0.5 ml/min. Content of GABA was deter-
mined with fluorescent detection (Waters® model 474) by peak
height measurements against standard solutions (Kendrick et al.,
1988).
The pellets obtained from the centrifugation process were used
to determine the amount of proteins (Lowry et al., 1951), a
situation that allowed expressing in micromoles per milligram
of proteins the values resulting from the fluorometric HPLC
procedure.
STATISTICAL ANALYSIS
The results obtained were expressed as mean± SE and analyzed
employing ANOVA test and Bonferroni post hoc test. Pearson’s
correlation coefficients were estimated to establish the potential
impact of clinical factors such as patient’s age, age at seizure onset,
duration of epilepsy, and seizure frequency on the GABAergic
system.
RESULTS
CLINICAL CHARACTERISTICS
Anxiety and depression were detected in 10 patients with TLE.
Their clinical data were as follows (mean± SE): age of patients,
36.4± 3 years (ranged from 24 to 48 years); age at seizure onset,
14.2± 4.5 years; years of epilepsy duration,22.2± 3.3; and seizures
per month, 16.4± 4.5. Regarding pharmacological therapy that
these patients received during the epilepsy process and pre-surgical
period, the following information was identified: (a) 90% (n= 9)
received polytherapy [from 4 to 10 antiepileptic drugs (AEDs)]; (b)
80% (n= 8) were treated with AEDs that could induce psychiatric
adverse effects, such as depression (levetiracetam, primidone, zon-
isamide, topiramate, and phenobarbital); (c) 90% (n= 9) received
2 or more AEDs with GABAergic properties (clobazam, clon-
azepam, diazepam, levetiracetam, lamotrigine, valproic acid, phe-
nobarbital, and primidone); and (d) 80% (n= 8) were treated
with AEDs that could induce positive effects on the mood (val-
proic acid, carbamazepine, and gabapentin). Four patients (40%)
had been previously diagnosed with depression and treated with
antidepressant drugs (amitriptyline, duloxetine, sertraline, or flu-
oxetine) during 9 months to 6 years before the epilepsy surgery.
Six patients (60%) were diagnosed with anxiety and/or depres-
sion during the pre-surgical evaluation, but they did not receive
pharmacotherapy for these disorders (Table S1 in Supplementary
Material).
Preclinical evaluation did not reveal neuropsychiatric comor-
bidity in 16 patients with pharmacoresistant TLE. Their clinical
data (age, 30.6± 2.2 years old, ranged from 17 to 60 years old;
age at seizure onset, 12.6± 2.1 years; years of epilepsy duration,
18.9± 3.1; and seizures per month, 16.5± 5.7) were not sig-
nificantly different when compared to those patients with TLE
and comorbid anxiety and/or depression. The pharmacological
therapy that these patients received during the epilepsy process
and pre-surgical period was similar to that administered to the
patients with TLE and comorbid anxiety and depression: (a) 75%
(n= 12) received polytherapy (from 3 to 7 AEDs); (b) 50% (n= 8)
were treated with AEDs that may produce mood disorders; (c) 81%
(n= 13) received 1 or more AEDs with GABAergic effects, and (d)
81% (n= 13) were treated with AEDs that induce a positive effect
on the mood (Table S1 in Supplementary Material).
The mean age of patients with TLE with and without anx-
iety and/or depression was similar to the mean age of autop-
sies (39.5± 3.4 years, ranging from 29 to 51 years, p< 0.51) and
patients with cerebral tumor without epilepsy and psychiatric
disorders (39.6± 6.6 years, ranging from 25 to 63 years, p< 0.6)
(Table S1 in Supplementary Material).
Nissl staining revealed a normal cytoarchitecture with no evi-
dent neuronal cell loss, cortical dysplasias, malformations, or
tumor in the different tissues evaluated.
CONTROL AND AUTOPSY SAMPLES
Samples obtained from control patients with tumor without
epilepsy presented 20.3± 1.3µM/mg of protein of GABA tissue
FIGURE 1 | (A) γ-Aminobutyric acid (GABA) tissue content in temporal
neocortex of control subjects and from patients with TLE with (A/D) and
without anxiety and depression (No A/D). (B) Correlation between the
frequency of seizures and the GABA tissue content in the temporal
neocortex of patients with TLE with ( ) and without (X) anxiety and
depression. r indicates the Pearson coefficient value. Values are expressed
as mean±SE of micromoles per milligram of protein. *p< 0.05 vs. control.
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FIGURE 2 | Photomicrograph of a Nissl-stained section (showing
layers I–VI) and pseudo-color autoradiographs obtained from an
autopsy sample. Autoradiographs show the distribution of binding to
GABAA and GABAB receptors as well as benzodiazepine (BDZ) sites, labeled
with [3H]-Muscimol, [3H]-CGP54626, and [3H]-Flunitrazepam, respectively.
High binding appears as red and orange areas, low binding is indicated as
yellow and green areas, whereas blue areas represent absence of binding.
levels (Figure 1). In autopsy samples, binding to [3H]-Muscimol
(GABAA receptors) was widely distributed through the various
cortical layers. Binding to [3H]-CGP54626 (GABAB receptors)
demonstrated a gradient across the cortical layers, showing the
highest in outer layer. Binding to [3H]-Flunitrazepam (BDZ
sites) was elevated in outer and middle layers (Figure 2 and
Table 2). Functional autoradiography revealed [35S]GTPγS incor-
poration as consequence of the GABAB-induced G-protein acti-
vation (153% in layers I–II, 130% in layers III–IV, and 137% in
layers V–VI) (Table 2).
In autopsy samples, the mRNA expression of the GABAA recep-
tor subunits was unrelated to the age of the subjects and time
required to obtain the tissue. High mRNA levels were observed
for subunits β1, β2, β3, and γ1, whereas subunits α1–6, γ2, and γ3
were less prominent.
PATIENTS WITH TLE
Patients with TLE without psychiatric disorders presented a non-
significant decrease of the GABA tissue content (22%, p> 0.05)
when compared to the autopsies. In contrast, the temporal neocor-
tex of subjects with TLE and comorbid anxiety and/or depression
showed lower tissue content of this amino acid (42%, p< 0.05),
a situation that correlated with a higher seizure frequency
(r =−0.5822, p< 0.05, Figure 1).
Concerning binding evaluation, neocortex of patients with
TLE with and without anxiety and/or depression did not show
significant abnormalities in [3H]-Muscimol binding (Figure 3,
Table 2). Patients without comorbid psychiatric disturbances
showed higher [3H]-Flunitrazepam binding in all neocortex (lay-
ers I–II, 86%, p< 0.05; layers III–IV, 58%, p< 0.05; and layers
V–VI, 103%, p< 0.001) compared to autopsies. In these patients,
Table 2 | [3H]Ligand binding to GABAA and GABAB receptors as well as
BDZ site, and GABAB-induced G-protein activation in specific cortical
layers of autopsies and samples of patients with temporal lobe
epilepsy with (A/D) and without (No A/D) anxiety and depression.
Binding Group Layers I–II Layers III–IV Layers V–VI
GABAA receptor Autopsy 468±18 486±29 359±17
A/D 465±50 434±40 365±29
No A/D 447±40 463±43 353±32
GABAB receptor Autopsy 7747±119 461±61 262±15
A/D 927±139 934±134** 500±88**
No A/D 1051±106 805±58** 503±42**
BDZ site Autopsy 563±91 648±108 369±62
A/D 701±136 784±126 494±80
No A/D 1052±115∗ 1024±78* 747±56***
GABAB-induced
G-protein
activation
Autopsy 153±28 130±15 137±10
A/D 81±14* 57±12** 74±9**
No A/D 152±24 110±14 92±9*
Binding values are expressed as mean±SME of fmol/mg of protein. The results
of the GABAB-induced G-protein activation are expressed as mean±SME of
percentage of specific [35S]GTPγS binding with respect to basal value (100%).
Statistical comparison was made using ANOVA and a post hoc Bonferroni test.
* p< 0.05; **p<0.01; ***p<0.001, when compared with autopsy group.
FIGURE 3 | Polar plots showing in percentage mean relative changes in
binding to GABAA receptors (- - - line) and benzodiazepine (BDZ) sites
(——- line) in temporal neocortex (layers I–II, III–IV, and V–VI) of patients
withTLE with (A/D, left side) and without (No A/D, right side) anxiety
and depression, with respect to autopsies (100%). *p<0.05,
***p< 0.001.
the higher [3H]-Flunitrazepam binding correlated with a lower
seizure frequency (layers I–II, r = 0.6582, p< 0.01; and layers III–
IV, r = 0.6672, p< 0.01) and a shorter duration of epilepsy (layers
III–IV, r = 0.5285, p< 0.05; layers V–VI, r = 0.4914, p< 0.05)
(Figure 4). [3H]-Flunitrazepam binding in neocortex of patients
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FIGURE 4 | Correlation between the frequency of seizures and
benzodiazepine (BDZ) binding (cortical layers I–II and III–IV, upper
panels), and duration of epilepsy and BDZ binding (cortical layers I–II and
III–IV, lower panels) of patients withTLE with ( ) and without (X)
anxiety and depression. r indicates the Pearson coefficient value. *p<0.05,
**p<0.01.
with TLE and anxiety and/or depression was not significantly
different from autopsy group (Figure 3; Table 2).
RT-PCR experiments revealed high α4-subunit expression
(114%, p< 0.05) in temporal neocortex of patients with TLE
without mood disorders when compared with autopsies. The
expression of the β-subunitis was not modified, whereas the γ2-
subunit expression was increased in patients with (126%,p< 0.05)
and without mood disorders (130%, p< 0.05).
[3H]-CGP54626 binding was increased in both, patients with
(layers III–IV, 102%, p< 0.01; layers V–VI, 88%, p< 0.01) and
without anxiety and/or depression (layers III–IV, 74%, p< 0.01;
layers V–VI, 90%, p< 0.01) (Figure 5; Table 2). In contrast,
[35S]GTPγS incorporation as consequence of activation of GABAB
receptors was lower in all cortical layers of patients with TLE and
comorbid anxiety and/or depression (layers I–II, 47%, p< 0.05;
layers III–IV, 56%, p< 0.01; and layers V–VI, 46%, p< 0.01)
(Figure 5 and Table 2). In these patients, the lower GABAB-
induced [35S]GTPγS incorporation correlated with a higher
seizure frequency (layers III–IV, r = 0.7380, p< 0.05; layers V–
VI, r = 0.8859, p< 0.01). Patients without psychiatric distur-
bances showed a lower GABAB-induced [35S]GTPγS incorpora-
tion restricted to deep layers (V–VI, 33%, p< 0.05) (Figure 5;
Table 2), a situation that correlated with a higher seizure fre-
quency (r = 0.5317, p< 0.05) and a longer duration of epilepsy
(r = 0.4975, p< 0.05).
DISCUSSION
Previous reports indicate important changes of the GABAergic
neurotransmission in the neocortex of patients with TLE (Avoli
et al., 1995; Koepp et al., 2000; Teichgräber et al., 2009). However,
data concerning abnormalities on the GABA receptor binding in
the lateral temporal neocortex of patients with pharmacoresistant
TLE are still controversial (la Fougère et al., 2009). The results
obtained in the present study could explain this disagreement sug-
gesting that specific alterations in the neurotransmission mediated
by GABA in the temporal neocortex of subjects with pharmacore-
sistant TLE are associated with the comorbidity of anxiety and/or
depression. Our results also indicate that clinical factors such as
seizure frequency and epilepsy duration may play an important
role in the disturbances of the GABAergic system in the temporal
neocortex of patients with pharmacoresistant TLE and comorbid
anxiety and/or depression.
[3H]-Muscimol binds to the same site on the GABAA recep-
tor complex as GABA itself (Frølund et al., 2002), and it labels
extrasynaptic GABAA receptors containing δ- and α4-subunits
(Chandra et al., 2010). Extrasynaptic receptors are relevant sen-
sors for ambient GABA and modulate the tonic inhibition (Nyitrai
et al., 2006). We found no significant changes in [3H]-Muscimol
binding in the neocortex of patients with TLE, regardless of the
presence of anxiety and/or depression, suggesting that the binding
to extrasynaptic GABAA receptors containing δ- and α4-subunits
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 442 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rocha et al. GABA, epilepsy, and comorbid anxiety and depression
FIGURE 5 | Polar plots showing in percentage mean relative changes in
GABAB receptor binding (- - - line) and GABAB-induced G-protein
activation (——- line) in the temporal neocortex (layers I–II, III–IV, and
V–VI) of patients withTLE with (A/D, left side) and without (No A/D,
right side) anxiety and depression, with respect to autopsies (100%).
*p<0.05, **p< 0.01.
is not altered and the GABAergic neurotransmission is preserved.
Indeed, our RT-PCR experiments revealed enhanced expression
of the mRNA encoding the α4-subunit in patients without anxiety
and/or depression, a situation that could be related to enhanced
tonic inhibition or may merely reflect compensatory changes.
[3H]-Flunitrazepam is a BDZ that labels GABAA receptors
containing γ2-subunit in combination with α1–3 subunits and
are responsible for mediating phasic inhibition at synaptic sites
(Lavoie and Twyman, 1996). BDZ can functionally potentiate
the effects induced by sub-maximal concentrations of GABA
by enhancing GABA affinity (Olsen, 1981). Previous studies in
patients with TLE indicate an increased expression of γ2-subunit
(Sperk et al., 2009), whereas the BDZ binding results are contro-
versial (la Fougère et al., 2009). From our results, it seems that
patients with TLE and mood disorders demonstrate absence of
changes in BDZ binding in the temporal neocortex, but an upreg-
ulation of γ2-subunit. It remains to be elucidated whether, in these
patients, the upregulation of γ2-subunit in temporal neocortex is
primary or is secondary to the disease, and represents a compen-
satory response to the GABA deficit. Concerning patients with
TLE without anxiety and depression, we found augmented BDZ
binding and increased expression of γ2-subunits. This situation
can be associated with fast synaptic GABA-induced inhibition and
reduction in anxiety-like and depressive-like behaviors (Earnheart
et al., 2007; Vithlani et al., 2013).
In agreement with the increased expression of the α4- and γ-
subunits, and the absence of changes in GABAA/BDZ binding
found in the present study, results obtained from other authors
using resected hippocampal tissue from patients with TLE sup-
port the idea that the inhibition mediated by GABAergic system
is conserved or even augmented (Babb et al., 1989; Mathern et al.,
1995). However, an important condition to be considered is that a
low ambient GABA represents an inadequate situation to activate
GABAA receptors mediating tonic inhibition with a consequent
facilitation of seizure activity, depression-like, and anxiety-like
behaviors (Merali et al., 2004; Maguire and Mody, 2008; Hines
et al., 2012). Our experiments revealed reduced GABA tissue lev-
els in the neocortex of patients with TLE and comorbid anxiety
and depression, a situation that can be associated with the low
GABA release in pharmacoresistant epilepsy described by other
authors (During and Spencer, 1993; Luna-Munguia et al., 2011).
Activation of GABAB receptors starts several signaling cas-
cades at pre- and postsynaptic levels essential for the stability of
the cortical network activity and modulation of gamma oscilla-
tions essential for cognitive processes (Kohl and Paulsen, 2010).
In contrast, a deficiency in the neurotransmission mediated by
GABAB receptors has been associated with changes in cortical
gamma oscillations with consequent psychiatric disorders such as
schizophrenia (Uhlhaas and Singer, 2010). We found that patients
with TLE without anxiety and/or depression presented decreased
GABAB-induced G-protein activation restricted to layers V–VI. In
contrast, patients with TLE and comorbid anxiety and/or depres-
sion showed reduced GABAB receptor-induced G-protein activa-
tion in all cortical layers. These findings associated with low GABA
tissue content suggest a deficit in the neurotransmission induced
by GABAB receptors in temporal cortex of patients with TLE and
comorbid anxiety and/or depression, a situation similar to that
found in patients with mood disorders (Enna and Bowery, 2004;
Croarkin et al., 2011). Indeed, the high GABAB binding found
in cortical layers III–IV and V–VI (present study), as well as the
up-regulation of GABAB in remaining neurons in hippocampus
(Princivalle et al., 2002) can represent a compensatory mechanism
resulting from the deficient neurotransmission mediated by these
receptors in patients with TLE.
The comorbidity of mood disorders in patients with epilepsy
has been associated with a higher perception of side effects of
the therapy with AEDs (Gómez-Arias et al., 2012). AEDs ther-
apy can induce uncoupling of GABA/BZD site interactions and
alterations in GABAA and GABAB function (Mula and Sander,
2007); these changes may result from the repetitive administra-
tion of BDZs and/or AEDs that enhance GABA exposure such as
tiagabine and vigabatrin (Suzuki et al., 1991; Gravielle et al., 2005;
Pericic´ et al., 2007). Carbamazepine and valproic acid increase the
number of GABAB binding sites in the rat hippocampus when
applied chronically, an effect that has been associated with the
mood stabilizing effects induced by these drugs (Motohashi,1992).
In contrast, long-term exposure to these AEDs may decrease the
GABAB receptor function, an effect analogous to that produced
by the subchronic administration of baclofen (Pacey et al., 2011).
Our results do not support a significant association between the
pharmacotherapy with AEDs inducing GABAergic effects in tem-
poral neocortex and the comorbid anxiety and/or depression in
patients with TLE. However, future studies including other brain
areas and a larger number of patients should be carried out to
support this hypothesis.
Affective disorders have been associated with disturbances in
the second messenger signaling via G-protein function (Pacheco
et al., 1996). Hyperfunction of G proteins leads to characteris-
tics of a manic or depressive state caused by instability in the
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activities of protein kinases C (Avissar and Schreiber, 1992), a
family of enzymes that are involved in the signal transduction
mechanism of the GABAB receptors (Taniyama et al., 1992). This
study indicates an imbalance of the G-protein activation induced
by stimulation of GABAB receptors in the temporal neocortex of
patients with TLE and comorbid anxiety and/or depression. This
situation should be kept in mind when considering these recep-
tors as promising targets for the therapy of psychiatric disorders
associated with TLE.
The comorbidity of mood disorders in TLE has also been
related to a higher seizure frequency (Grabowska-Grzyb et al.,
2006; Mula and Sander, 2007; Peng et al., 2014) and longer
duration of active epilepsy (Gonçalves and Cendes, 2011). Our
results revealed that the lower values for BDZ binding, GABAB-
induced G-protein activation, and GABA tissue content corre-
lated with a higher seizure frequency and the longer duration
of epilepsy of patients with TLE and comorbid anxiety and/or
depression. In contrast, the higher BDZ binding and elevated
GABAB-induced G-protein activation correlated with a lower
seizure frequency of patients with TLE without psychiatric dis-
turbances. It is possible that the higher seizure frequency and
longer duration of epilepsy augment the exposure to elevated
extracellular GABA levels during the ictal period. This situation
may result in GABAA desensitization, dysregulation of the neuro-
transmission mediated by GABAB receptors, and uncoupling of
GABA/BZD site interactions (Gravielle et al., 2005), conditions
that could facilitate the comorbid anxiety and/or depression of
patients with TLE. Finally, further experiments should be car-
ried out to identify if the receptor binding alterations detected
in the present study are the consequence of changes in the num-
ber or affinity of the receptors evaluated. We also suggest future
studies in patients with anxiety and depression disorders but
without epilepsy to explain the findings obtained in the present
study.
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